In 2018, double digit growth for prioritized brands Opdivo, which grew by $443 million, Eliquis, which grew by $342 million, Yervoy, which grew by $115 million, as well as Orencia, helped to offset significant declines in established brands Baraclude,
Reyataz, Sustiva, and Hepatitis C franchises (for which revenues have all but disappeared), representing a total of $1.5 billion in lost revenue as compared to 2017.
During his time at BMS, He played an integral role in several virology programs in both HIV and HCV, including helping launch several medicines such as
Reyataz, Sustiva and Daklinza.
(6.)
Reyataz [package insert], Princeton, NJ: Bristol-Myers Squibb Company; 2017.
Total use of anti-HIV protease inhibitors (like Prezista or
Reyataz) or the antiretroviral tenofovir (a part of combination drugs like Stribild and Atripla) was not linked to rates of all fractures or fragility fractures.
The other member of the $ 1 billionplus club losing protection this year is Bristol-Myers Squibb Co.'s HIV drug,
Reyataz, which accounted for $1.14 billion annually.
All subjects were on antiretroviral regimens based upon either darunavir (Prezista), atazanavir (
Reyataz), raltegravir (Isentress), or dolutegravir (Tivicay).
Protease inhibitor regimens
Reyataz ATV-rplus atwo-NRTI Maternal backbone hyperbilirubinemia.
This breakthrough therapy designation is based on data from the company's Phase IIb clinical study comparing BMS-663068 to a boosted protease inhibitor (
Reyataz (atazanavir sulfate) and ritonavir) in treatment-experienced patients, with a treatment backbone across all arms of raltegravir, in addition to tenofovir disoproxil fumarate.
Prescriptions per month for drugs in each group before and after the new guidelines (mean n) Group 1, Group 1, Group 2, Group 3, Post-2010, Drug pre-2010 post-2010 post-2010 post-2010 combined mean Abacavir 1.00 0.92 0.00 3.08 1.33 Aluvia 6.00 11.04 16.29 10.00 12.44 Combivir 2.17 2.63 0.46 0.17 1.09 DDI 1.42 2.63 2.42 0.00 1.68 EFV 57.67 60.79 61.88 64.25 62.31 3TC 61.17 63.38 68.58 64.42 65.46 NVP 3.50 2.67 0.78 0.92 1.46
Reyataz 0.00 0.75 1.46 1.00 1.07 D4T 49.50 35.42 32.96 17.00 28.46 TDF 4.17 20.75 30.21 38.83 29.93 Truvada 2.50 6.46 8.00 13.17 9.21 AZT 7.92 8.71 8.50 6.00 7.74 DDI = didanosine; EFV = efavirenz; 3TC = lamivudine; NVP = nevirapine; D4T = stavudine; TDF = tenofovir; AZT = zidovudine.
ATV, an azapeptide, was developed originally by Ciba-Geigy and sold under the trade name
Reyataz by Bristol-Myers Squibb.